Neuronetics Q1 2026: Cash Burn Shrinks, Revenue Grows, and a Policy Pivot Nudges the TMS Market
Ticker: STIM. In its first-quarter 2026 release, Neuronetics reports EPS considerations without an explicit EPS figure, and the company offers no formal revenue forecast. The press release still moves the story: revenue of about $34.5 million, a tighter cash burn, and a meaningful policy tailwind that could expand access to NeuroStar therapy. It’s the kind of data set that invites an earnings surprise discussion only if the market learns the company’s true EPS trajectory from subsequent quarters.
Overview: what the numbers say in plain English
Neuronetics (STIM) posted first-quarter 2026 revenue of $34.5 million, up roughly 8% from the same period a year earlier. Within that, U.S. clinic revenue reached about $21.5 million, a 15% year-over-year increase. The company shipped 34 NeuroStar systems in the United States, marking a 10% year-over-year lift in unit sales. On the cash side, net cash used in operations was $9.4 million, a significant improvement versus $17.0 million in Q1 2025. Translation: the burn rate is coming down while top-line momentum holds.
The release stresses a shift in cash flow dynamics rather than a dramatic swing in profitability. No forward-looking revenue forecast or explicit EPS guidance accompanies the numbers, which means investors must infer the trajectory from operating metrics and competitive positioning rather than a published EPS consensus for the near term.
Geography mix and what it implies for growth
The company presents a geography slice showing U.S. revenue dominance and smaller international contributions. In the three months ended March 31, 2026, U.S. revenue stood at approximately $34.2 million versus about $31.5 million in the prior year, underscoring a solid U.S. growth engine. International revenue remained very modest by comparison.
| Geography | 2026 Amount | 2025 Amount | % Change |
|---|---|---|---|
| U.S. | $34,226k | $31,483k | ≈9% |
| International | $228k | $492k | ≈-54% |
The U.S. strength aligns with a clinic-led growth model, while international execution remains a smaller, more variable piece of the puzzle. The takeaway: near-term momentum is impor tantly domestic, with a potential for international contribution if scaling efforts and payer access mature.
Operational highlights and strategic tailwinds
A notable operational highlight is the policy expansion by Optum/UHC/UBH to allow nurse practitioners to order, supervise, and administer NeuroStar Advanced Therapy. That kind of payer policy broadens the addressable market for NeuroStar in a way that monetary metrics alone can’t capture. If insurers move toward broader credentialing for TMS, the incremental patient flow could become a meaningful driver of utilization and installed base expansion.
The company’s leadership commentary underscores execution on revenue growth, cost discipline, and improved cash flow. The CEO emphasizes that the core advantages—leading TMS technology, a national clinic footprint, and a team focused on long-term value—are intact. In other words: the assets are robust, and the strategic levers are within reach of a scalable growth story.
What this portends for the sector and peers
The Optum/UHC/UBH policy expansion may serve as a bellwether for the sector: payer coverage shifts can unlock patient access without requiring a new product line. For Neuronetics, the policy tailwind could translate into higher utilization per clinic and faster growth in the installed base, assuming the reimbursement environment remains favorable.
From a competitive standpoint, peers in the transcranial magnetic stimulation (TMS) space will watch not only the growth-rate numbers but the real-world usage signals implied by policy expansion and physician ordering authority. In this dynamic, EPS trajectory becomes a function of leverage—how well a company converts growing demand into achievable operating earnings, not just top-line gains.
Takeaway for investors and the “EPS conversation”
The quarter shows solid momentum on revenue and a healthier cash trajectory, set against the backdrop of a policy environment that can meaningfully expand the addressable market. While the release does not provide an EPS figure or a formal EPS consensus or earnings surprise metric for Q1 2026, the improving cash flow and higher utilization hint at potential upside if payer coverage and clinic volumes persist. The lack of a stated revenue forecast leaves the stock price to be driven by execution signals and insurer-policy developments rather than near-term guidance.